L01EX02 • sorafenib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Sorafenib is an antineoplastic medication used for the treatment of certain types of cancer, such as hepatocellular carcinoma, advanced renal cancer, and differentiated thyroid cancer. It works by inhibiting multiple kinases involved in tumor growth and angiogenesis.
The medication is taken orally, as directed by a doctor, usually twice daily. It is important for patients to adhere to the treatment regimen and undergo regular check-ups to monitor the response to therapy.
Patients should be aware of potential side effects, such as diarrhea, fatigue, or high blood pressure. It is important to inform the doctor of any unusual symptoms.
Common side effects include diarrhea, fatigue, high blood pressure, and skin rashes. In rare cases, severe reactions such as liver injury syndrome or allergic reactions may occur. Patients should be informed of these risks before starting treatment.
Substance: sorafenib
Date of last drug list: 01-09-2023
Commercial code: W67070001
Concentration: 200mg
Pharmaceutical form: tablets
Quantity: 112
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: REMEDICA LTD - CIPRU
Holder: MYLAN IRELAND LIMITED - IRLANDA
Number: 13465/2020/01
Shelf life: 2 years